MOH (Iraq)

The Iraq Ministry of Health is the federal authority for human medicines, biologicals, vaccines, medical devices, in vitro diagnostics, cosmetics, dietary supplements, pharmacy practice, and controlled substances across the Republic of Iraq. Its regulatory functions are principally executed through the Technical Affairs Directorate, supported by the National Center for Drug Control and Research (NCDCR) for quality control, the Iraqi Pharmacovigilance Center for safety monitoring, and Kimadia, the state company responsible for large‑scale public‑sector procurement and distribution.

The legal basis combines legacy statutes and ministerial instruments. Law 40 of 1970 establishes pharmacy practice and pharmaceutical establishments oversight, while Law 68 of 1965 governs narcotics and psychotropics, reflecting alignment to the UN Single Convention of 1961 and the 1971 and 1988 conventions. Subsequent Ministerial Orders and Technical Affairs Directorate decisions define registration, inspection, pricing, import controls, and vigilance procedures applicable to domestic and foreign manufacturers and their authorized Iraqi agents.

The Ministry is headquartered in Baghdad and reports to the Council of Ministers through the Minister of Health. Kimadia’s public‑sector role is distinctive in the region: it aggregates demand, tenders nationally, and manages distribution to public hospitals and clinics, which shapes market access and supply planning for sponsors. Parallel to the federal system, domestic manufacturers are rebuilding capacity, and the private sector continues to supply a substantial share of medicines via imports.

The Kurdistan Region of Iraq (KRI) operates a constitutionally distinct Ministry of Health headquartered in Erbil with meaningful autonomy over drug registration, procurement, and pharmacy practice across Erbil, Sulaymaniyah, and Duhok. Sponsors should anticipate both federal and KRI interactions for comprehensive Iraqi market coverage and factor this into regulatory, labeling, and distribution strategies.

MoH jurisdiction covers prescription and nonprescription medicines, vaccines, plasma‑derived and other biologicals, medical devices and IVDs across risk classes, cosmetics, dietary supplements, disinfectants, and pharmacy operations. Importers and marketing authorization holders must be locally licensed and are responsible for product registration, batch release logistics, quality complaints, and recalls. NCDCR conducts pre‑ and post‑market testing as part of registration and market surveillance, with sampling often required for tenders and pricing actions.

For human medicines, dossiers generally align to CTD structure for quality, nonclinical, and clinical evidence. Vaccines and WHO‑prequalified products may benefit from collaborative mechanisms that shorten national review when reliance is permitted. Devices and IVDs rely on classification, safety and performance documentation, and quality management system evidence, while cosmetics and supplements undergo labeling and composition checks with documentation tailored to risk and intended use.

Controlled substances require additional permits tied to quotas and strict recordkeeping. Across all categories, Arabic labeling, storage conditions, and traceability through licensed wholesalers are baseline expectations. Where humanitarian agencies operate, separate exemptions or expedited channels may apply, without displacing core safety and quality obligations.

Sponsors pursuing marketing authorization for small molecules and biologicals should prepare a dossier consistent with CTD principles. Quality documentation is central, including drug substance and drug product specifications, stability, process validation summaries, and Good Manufacturing Practice evidence for each site. Iraq’s authorities typically rely on documentary GMP confirmations and may request inspection histories or certificates from stringent regulators where available, while reserving the right to conduct their own verification.

NCDCR performs independent laboratory testing on submitted samples to verify identity, assay, impurities, and other critical attributes before or during registration and sometimes prior to public procurement cycles. USP, European, or other pharmacopeial methods are generally accepted references when aligned with the registered specification, and method validation summaries are expected where compendial methods are adapted. Batch‑specific release to the Iraqi market must be consistent with the registered limits and the results of state testing.

For vaccines and other WHO‑prequalified products, Iraq participates in reliance pathways such as the WHO Collaborative Registration Procedure, enabling abridged assessments by referencing the WHO assessment and inspection outcomes. Sponsors should ensure timely sharing of PQ assessment reports, lot release documentation, and stability updates to support CRP timelines and national batch oversight.

After approval, pricing and procurement steps follow, with Kimadia playing a central role in public‑sector demand aggregation. Private‑sector channels require distribution through licensed importers and wholesalers with appropriate storage and transport controls. Lifecycle maintenance includes variation management, renewals, and pharmacovigilance reporting aligned with global practices under ICH guidelines.

Useful references for dossier and quality expectations include WHO GMP guidance, ICH quality guidelines, and human regulatory procedural guidance used internationally. Sponsors that map their submissions to these frameworks typically experience fewer clarification rounds and faster procurement alignment once authorized.

Cross‑functional readiness benefits from adopting structured quality systems and continual improvement approaches consistent with international best practice, which simplifies both initial review and subsequent post‑approval changes.

See related concepts: who-gmp-trs-1044-2022 and ICH concepts echoed in post-market-surveillance planning.

Medical devices and IVDs are overseen by the devices unit within the Technical Affairs Directorate. Submissions are risk‑stratified, with higher‑risk classes requiring more extensive safety and performance evidence and robust quality system documentation. A comprehensive technical file is expected to demonstrate conformity with essential safety and performance requirements, supported by test reports, clinical evidence proportional to risk, and complete labeling in Arabic and English as appropriate.

Manufacturers are generally expected to operate a quality management system consistent with ISO 13485. Evidence of conformity to recognized standards for biocompatibility, electrical safety, software lifecycle, sterilization, and packaging validation is typically part of the review. For IVDs, analytical and clinical performance evidence must show that intended use claims are met across relevant populations and matrices.

Although Iraq defines its own requirements, approvals or conformity assessments from reference jurisdictions can inform national review. Sponsors often present EU technical documentation, FDA authorizations, or comparable reference market evidence to substantiate safety and effectiveness, noting that local authorities may still require clarifications, supplemental testing, or label modifications to address national needs.

Post‑market obligations include vigilance reporting and corrective actions, field safety notices, and complaint trend analysis, coordinated with distributors and health facilities. Importers must ensure correct storage and transport, and maintain traceability to enable effective recalls and adverse event investigations.

Related reading: medical-device-classification, technical-file, and staged development approaches in medical-device-development-phases.

Controlled substances fall under Law 68 of 1965 and ministerial instruments that implement Iraq’s obligations under the international drug control conventions. Import, manufacture, distribution, and dispensing are tightly regulated through quota‑based permits, end‑use declarations, and stringent custody and recordkeeping requirements. Healthcare facilities must designate responsible pharmacists and secure storage that meets prescriptive physical controls.

Applications typically include source and strength details, annualized quantities, security measures, and diversion‑prevention procedures. Movement between facilities requires authorization, reconciled documentation, and periodic reporting. Destruction of expired or damaged stock must follow MoH‑approved procedures with witnessed counts and retained certificates.

Sponsors and distributors should embed internal controls consistent with international best practices, including inventory reconciliation, exception alerts, and rapid escalation of discrepancies. Training for pharmacists and logistics staff is essential to maintain compliance during audits and to prevent diversion.

After approval and import, marketing authorization holders and distributors must operate robust pharmacovigilance and quality systems. The Iraqi Pharmacovigilance Center collects adverse event reports from healthcare professionals and companies, feeds signals into the WHO Programme for International Drug Monitoring, and coordinates risk minimization and safety communications with the Technical Affairs Directorate.

NCDCR continues post‑market sampling and testing to verify quality, particularly for high‑risk products, vaccines, injectables, and tenders supplying large patient populations. Wholesalers and hospital pharmacies must follow good distribution and storage practices, including temperature control, security, and stock rotation, with documentation that supports traceability and timely recalls.

Device and IVD vigilance relies on rapid incident reporting, root‑cause investigation, and field safety corrective actions. Sponsors should maintain complaint trending, implement corrective and preventive actions, and keep technical files current with post‑market data, including real‑world performance and labeling updates where risk–benefit evolves.

Humanitarian operations and special import channels can expedite access during emergencies, yet do not waive safety, quality, or traceability requirements. Sponsors supplying these programs should pre‑plan documentation, cold‑chain validation, and recall coordination protocols to satisfy both donors and the MoH.

Useful anchors for system design include pharmacovigilance processes in pharmacovigilance, lifecycle safety in post-market-surveillance, distribution controls in eu-gdp-good-distribution-practice-readiness, and cold‑chain monitoring practices akin to temperature-monitoring-pharma.

• Maintain a national safety contact and submit expedited and periodic reports per Iraqi instructions.
• Ensure traceability from importer receipt through hospital dispensing with documented lot control.
• Qualify and monitor distributors, transporters, and storage sites, including temperature mapping.
• Execute recalls swiftly with notification to MoH, clear retrieval plans, and reconciliation records.
• Trend quality complaints, implement CAPA, and update registered specifications where needed.

Kimadia is Iraq’s state company for procuring and distributing medicines, vaccines, and medical supplies to public facilities. It aggregates national demand, publishes tenders, evaluates bids for technical and commercial compliance, and distributes awarded products through its network. Registration is typically a prerequisite to compete, and tenders may request samples for NCDCR evaluation, batch histories, performance guarantees, and post‑award delivery schedules.

Private‑sector access operates through licensed importers and wholesalers that supply community pharmacies and private hospitals. Pricing policies, reimbursement mechanisms, and local market dynamics influence volumes outside Kimadia. Sponsors often blend public and private strategies, using tenders to secure baseline volume while cultivating private demand for differentiated products.

In the Kurdistan Region, the KRI MoH manages its own procurement and distribution. While some national programs coordinate across jurisdictions, sponsors should anticipate separate tender notices, submission formats, and delivery logistics to serve facilities in Erbil, Sulaymaniyah, and Duhok.

Operational readiness for tenders depends on dossier quality, supply continuity, and transparent cost structures. Maintaining responsive pharmacovigilance and recall capabilities is also a competitive factor, demonstrating reliability to procurement authorities and clinicians.

Sponsors new to Iraq often underestimate the time and documentation needed for state testing, Arabic labeling reviews, and procurement‑specific evaluations. Early alignment with a locally licensed agent, clear GMP evidence for each manufacturing site, and precise mapping of specifications to pharmacopeial monographs materially reduce friction during review and tendering.

Dual‑track planning for federal Iraq and the KRI is essential for nationwide access. Misassumptions about automatic acceptance of reference market approvals, or about the interchangeability of labels and pack inserts across jurisdictions, can lead to avoidable delays. Thorough planning for controlled distribution, complaint handling, and recall execution is expected and tested in practice.

• Submitting incomplete CTD sections or omitting site‑specific GMP documentation for subcontractors.
• Treating CE marking or FDA clearance as sufficient without Iraq‑specific technical justifications.
• Neglecting Arabic labeling nuances, including storage statements, excipient disclosures, and leaflet readability.
• Under‑resourcing sample logistics and NCDCR testing timelines ahead of tenders or launches.
• Assuming Baghdad authorizations automatically permit KRI marketing and distribution.
• Weak distributor oversight, temperature control, and traceability during inter‑governorate shipments.

Iraq actively participates in WHO Eastern Mediterranean regulatory initiatives, pharmacovigilance collaboration, and reliance pathways for WHO‑prequalified products. While it is not bound by Gulf Cooperation Council centralized procedures, Iraq engages in Arab regional dialogues that encourage convergence on dossier formats, quality standards, and vigilance practices without formal mutual recognition.

Sponsors frequently leverage evidence developed for the EU, United States, and other reference markets to support Iraqi submissions, aligning with international standards for GMP, device QMS, and pharmacovigilance. Adoption of distribution and manufacturing practices compatible with EU GDP and PIC/S guidance helps demonstrate system robustness during Iraqi inspections and audits.

For regional context, examine neighboring frameworks such as kuwait-moh, oman-moh, and syria-moh, as well as coordination touchpoints relevant to palestine-moh. Alignment to WHO reliance tools, the ICH quality canon, and sterile manufacturing practices consistent with pic-s-annex-1-alignment can smooth cross‑border operations, even where legal requirements differ.

Sponsors should avoid assuming equivalence. Each market retains sovereign requirements, and Iraq’s use of reliance is discretionary, subject to local benefit–risk, labeling, and supply assurance considerations. Early dialogue with local agents and careful mapping of evidence to Iraqi expectations is decisive.

Implementing Iraq MoH requirements efficiently demands synchronized document control, sample and testing coordination, vigilance readiness, and end‑to‑end lot traceability. V5 Ultimate centralizes registration dossiers, testing certificates, labeling artifacts, and change histories so teams can answer technical queries and tender clarifications without delay.

On the quality side, integrated workflows enforce approved specifications, govern batch release decisions, and capture distributor qualifications, storage mappings, and temperature excursions. Device and IVD manufacturers can maintain auditable technical files and ISO 13485 evidence with controlled updates, while pharmacovigilance and complaint data feed directly into post‑market surveillance and recall execution.

Commercial teams benefit from reliable master data, artwork control, and shipment‑level traceability, which align with MoH sampling, NCDCR testing, and Kimadia performance obligations. Dual‑jurisdiction labeling and procurement for Baghdad and the KRI can be handled as governed variants with synchronized change control and attribute‑based distribution rules.

Explore related capabilities including qms, controlled document-control, audit evidence via audit-readiness, supplier oversight with approved-supplier-list, secure weigh-and-dispense, and end‑to‑end traceability. Batch readiness and testing flow through qc-release, device records align to ebmr-edhr, and labs can coordinate NCDCR‑aligned methods through lab-qc.